March 2018 DT0318_Cover.jpg
Ustekinumab shows promise for reducing psoriasis-associated cardiovascular comorbidityInitial results of an investigator-initiated phase 4 trial suggest that blocking interleukin-12 (IL-12) and IL-23 may reduce cardiovascular inflammation associated with psoriasis, researchers reported at AAD 2018.
AAD insights and takeawaysIn this article, Dr. Norman Levine sums up his takeaways from the American Academy of Dermatology annual meeting, beginning with a presentation by two physicians who addressed the difficulties of managing hidradenitis suppurativa, such as fixed dosing. He also addressed controversies associated with treatments for atopic dermatitis. Apparently, bleach baths are no better than regular baths in improving skin symptoms.
I prescribe drugs off-label. Am I in violation of FDA regulationsIn a CME session through your local dermatology society, a prominent drug company provides journal articles documenting the off-label use of one of their prescription pharmaceutical agents. You obtain CME credits, read the journal article and begin prescribing the off-label medication. Is the drug company in violation of the U.S. Food and Drug Administration (FDA) rulings? Are your actions acceptable?
Are polymer-based specialty cleansers milder?Cleansing is a profound mechanical and chemical skin event. The challenge is to achieve skin hygiene without damaging the skin barrier, but smart surfactants are not yet reality.
Are facial toners necessary?Not really, says Dr. Zoe Draelos in this month's Cosmetic Conundrums. Toners are present in most commercial skin care products, but originally it was intended as a cleanser.
Stem cell transplant offers long-term hope for severe scleroderma patientsAn intensive stem cell transplant regimen achieved better survival as compared to cyclophosphamide treatment for patients with severe scleroderma, researchers report in the New England Journal of Medicine.
Atopic dermatitis: From guidelines to practiceThis week during the annual meeting of the American Academy of Dermatology in San Diego, Robert Sidbury, M.D., addressed developments in atopic dermatitis treatments since the publication of treatment guidelines in 2014.
Spironolactone for hormonal acneFemale patients with hormonal acne that typically flares before or after menstrual cycles may be ideal candidates for spironolactone, said Emmy M. Graber, M.D., president of the Dermatology Institute of Boston who spoke at AAD 2018 in San Diego this week.
Biologics offer promise for hidradenitis suppurativa treatmentWith one approved biologic available and many more under investigation, the future of treatment for hidradenitis suppurativa looks very promising.
Skin lupus can progress more rapidly than previously thoughtSystemic disease among patients with discoid lupus erythematosus, a chronic form of cutaneous lupus, can develop within one to two years of initial diagnosis, says Joseph F. Merola, M.D., reporting at the American Academy of Dermatology annual meeting in San Diego.
The promise of biologic therapy in dermatologyDuring the American Academy of Dermatology’s annual meeting, physicians addressed the monumental changes that have occurred since the advent of biologic therapy for systemic autoimmune conditions, such as psoriasis and atopic dermatitis. Today, some patients are able to achieve complete disease clearance. Although there may be viable treatments for these conditions, access to care and medication adherence remain top issues, physicians say.
From new vaccines to the advent of new neurotoxinsPhysicians weigh in expectations for new developments within all facets of dermatology from pediatric dermatology to dermatopathology.
Insights to improve your psoriasis care planKnowledge of outcomes data, adverse events may help physicians formulate effective treatment strategies, Dr. April Armstrong says.
Combination topical appears effective for subclinical actinic keratosis treatmentCombination of fluorouracil and salicylic acid may be an effective field treatment for subclinical actinic keratoses lesions.
Managing hedgehog therapies for basal cell carcinomaWhile the vast majority of basal cell carcinomas are treated and resolved with surgery, systemic therapy with one of the two hedgehog pathway inhibitors could be a treatment option for unresectable or metastasized disease, researchers reported at the American Academy of Dermatology annual meeting in San Diego this week.
Multidisciplinary care improves patient outcomesMultidisciplinary skin cancer care is an approach that might not only improve patient outcomes, but also professional satisfaction, researchers reported at AAD 2018 this week in San Diego.
Combination treatment for scars proves effectiveCombination treatments to reduce scarring have been shown to be effective without the need for aggressive surgical techniques that can lead to suboptimal results, researchers reported at AAD 2018 this week.
Dermatology journals among the 50 most cited for cosmetic proceduresThe review notes a rise in first authorships among dermatologists. From 2000-2014, dermatologist first authors accounted for 8% of the most often-cited facelift articles and 5% or less of the top blepharoplasty articles. They also accounted for approximately 12% of the top brow lift articles from 2000-2009.